Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00732615 · ClinicalTrials.gov registry record · Phase 3
Use of NPSP558 in the Treatment of Hypoparathyroidism
A Phase 3 study of Hypoparathyroidism, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 124
- Enrollment target
- 20
- Study locations
NCT00732615 is a Phase 3 study of Hypoparathyroidism that has completed, run by Shire. The registered enrollment target is 124 participants, below the 187-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT00732615, a Phase 3 study of Hypoparathyroidism, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 124 participants
- Enrollment target
- 20
- Study locations
Study Summary
Use of PTH (1-84) a recombinant hormone in escalating doses for the treatment of adults with hypoparathyroidism. The use of PTH should result in a decrease of calcium and vitamin D supplements.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NPSP558
Study Locations (20)
California
- Advance Medical Research LLC - Lakewood
- Diabetes Associates - Orange
- University of California-San Francisco VA Medical Center - San Francisco
Florida
- Palm Springs Research Institute - Hialeah
- Mayo Clinic Jacksonville - Jacksonville
New York
- Columbia University Medical Center - New York
- University Physicians Group - Staten Island
Texas
- Cetero Research DGD Research Inc. - San Antonio
- Hillcrest Family Health Center - Waco
Arizona
- Mayo Clinic-Scottsdale - Scottsdale
Illinois
- University of Chicago Medical Center - Chicago
Indiana
- Indiana University School of Medicine - Indianapolis
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2008-12-18 |
| Est. Completion | 2011-09-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00732615
The ClinicalTrials.gov registry entry for NCT00732615 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 187-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (34% lower). The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypoparathyroidism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00732615 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT00732615 about?
NCT00732615 is a clinical study titled "Use of NPSP558 in the Treatment of Hypoparathyroidism". Use of PTH (1-84) a recombinant hormone in escalating doses for the treatment of adults with hypoparathyroidism. The use of PTH should result in a decrease of calcium and vitamin D supplements.
What is the current status of trial NCT00732615?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 124 participants. The study started on 2008-12-18. Estimated completion is 2011-09-28.
What conditions does trial NCT00732615 study?
This clinical trial studies the following conditions: Hypoparathyroidism.
What interventions are being tested in trial NCT00732615?
The interventions under investigation include: Placebo (DRUG), NPSP558 (DRUG).
Who is sponsoring clinical trial NCT00732615?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00732615 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
RECRUITING
-
Hypoparathyroidism Natural History Study
RECRUITING
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
Parathyroid Allotransplant for Treatment of Hypoparathyroidism
RECRUITING · Phase 1
-
A Registry for Participants With Chronic Hypoparathyroidism
ACTIVE NOT RECRUITING
-
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.